Some recent FDA approvals have made many people aware of tumor-agnostic treatments. But what does that mean and how could it benefit someone with cancer? ASCO Chief Medical Officer Richard L. Schilsky gives insight into this new way of thinking about cancer treatment.
Kidney cancer is the sixth most common cancer for men and the tenth most common cancer for women. Cancer.Net Associate Editor Brian Rini, MD, shares 4 things people need to know about kidney cancer.
Cancer.Net Associate Editors discuss exciting and practice-changing cancer research from ASCO Annual Meeting in this Research Round Up podcast.
Lung cancer affects tens of thousands of Americans every year. In this blog post, Cancer.Net Associate Editor Dr. Jyoti Patel describes 9 things every person should know about lung cancer.
ASCO Annual Meeting 2018: New Insight Into Lynch Syndrome, Finding and Treating Lung Cancer, a New Targeted Therapy for Breast Cancer, and Evidence that Personalized Medicine Helps
Oncology professionals from around the globe are at the 2018 ASCO Annual Meeting. Today’s key research highlights address the connection between microsatellite instability and Lynch syndrome, a blood test that may be used to find early lung cancer, a new targeted therapy for treating advanced breast cancer, an immunotherapy-chemotherapy combination that slows lung cancer growth, and evidence that personalized medicine helps people with cancer live longer.
In this podcast, Dr. Gary Lyman describes biosimilars for cancer treatment and why they are important. He also talks about why ASCO is releasing a statement on them today.
In this podcast, Dr. Erica Mayer reviews research highlights from the San Antonio Breast Cancer Symposium. New insights into hormone therapy, targeted therapy, joint stiffness, and fertility preservation are covered.
In this podcast, Cancer.Net Associate Editor Dr. Michael Williams describes lymphoma research advances presented at the American Society of Hematology Annual Meeting.
In this podcast, Cancer.Net Associate Editor Ezra Cohen, MD, FRCPC, discusses some of the key themes that arose at the 2017 3rd World Congress on Thyroid Cancer.
ASCO Annual Meeting 2017: Advances in Immunotherapy for Multiple Myeloma and Mesothelioma, and Targeted Therapies for Non-Small Cell Lung Cancer and HER2-Positive Breast Cancer
Oncology professionals from around the globe are in Chicago for the ASCO Annual Meeting. Today’s key research highlights include CAR T-cell therapy for multiple myeloma, immune checkpoint inhibitors for mesothelioma, and targeted therapy advances for non-small cell lung cancer and HER2-positive breast cancer.